| Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 | Dec'15 | Sep'15 | Jun'15 | Mar'15 | Dec'14 | Sep'14 | Jun'14 | Mar'14 | Dec'13 | Sep'13 | Jun'13 | Mar'13 | Sep'12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Related Party Transaction | ||||||||||||||||||||||
Related Party Transaction | ||||||||||||||||||||||
Roche [Member] | ||||||||||||||||||||||
Product and Service | ||||||||||||||||||||||
Product and Service | ||||||||||||||||||||||
Molecular Information Services [Member] | ||||||||||||||||||||||
Pharma Research and Development Services [Member] | ||||||||||||||||||||||
Revenue: | ||||||||||||||||||||||
Revenue | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | 17,423 | - | 20,953 | 18,309 | 19,295 | - | 16,284 | 14,253 | - | - | - | - | - | - |
Related-party revenue | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | 12,955 | - | 4,446 | 4,149 | - | - | 164 | 243 | - | - | - | - | - | - |
Total revenue | ||||||||||||||||||||||
57,006 | 52,840 | 48,913 | 42,658 | 35,004 | 26,328 | 28,824 | 29,426 | 28,237 | 30,378 | 26,051 | 25,399 | 22,458 | 19,295 | 18,680 | 16,448 | 14,496 | 11,455 | 9,662 | 8,208 | 5,920 | 5,200 | 3,037 |
Costs and expenses: | ||||||||||||||||||||||
Cost of molecular information services | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | 10,028 | - | 9,068 | 8,950 | 8,916 | 8,022 | 7,502 | 6,619 | 5,291 | 4,204 | 2,858 | 2,219 | 2,378 | 1,791 |
Cost of related-party molecular information services from Roche | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | 1,362 | - | 1,302 | - | - | - | - | - | - | - | - | - | - | - |
Selling and marketing | ||||||||||||||||||||||
17,141 | 17,480 | 16,620 | 16,556 | 17,115 | 16,436 | 15,023 | 14,654 | 14,481 | 13,793 | 12,400 | 14,267 | 12,542 | 9,821 | 8,244 | 7,893 | 7,170 | 5,690 | 4,602 | 3,038 | 2,875 | 1,811 | 849 |
General and administrative | ||||||||||||||||||||||
19,771 | 20,695 | 20,414 | 17,001 | 17,648 | 15,277 | 13,872 | 13,012 | 12,503 | 9,224 | 8,804 | 9,199 | 23,769 | 8,842 | 8,976 | 6,801 | 5,825 | 5,700 | 7,512 | 6,448 | 4,755 | 3,150 | 2,134 |
Research and development | ||||||||||||||||||||||
24,702 | 23,859 | 22,852 | 22,399 | 22,973 | 23,285 | 18,177 | 17,238 | 18,500 | 13,456 | 12,765 | 12,174 | 10,256 | 8,688 | 7,839 | 7,230 | 8,645 | 6,915 | 6,834 | 6,988 | 6,097 | 4,982 | 3,567 |
Total costs and expenses | ||||||||||||||||||||||
89,090 | 89,261 | 86,429 | 75,084 | 79,318 | 73,015 | 64,529 | 60,850 | 57,439 | 47,863 | 45,164 | 46,010 | 55,517 | 36,267 | 33,081 | 29,426 | 28,259 | 23,596 | 23,152 | 19,332 | 15,946 | 12,321 | 8,341 |
Loss from operations | ||||||||||||||||||||||
-32,084 | -36,421 | -37,516 | -32,426 | -44,314 | -46,687 | -35,705 | -31,424 | -29,202 | -17,485 | -19,113 | -20,611 | -33,059 | -16,972 | -14,401 | -12,978 | -13,763 | -12,141 | -13,490 | -11,124 | -10,026 | -7,121 | -5,304 |
Interest (expense) income, net | ||||||||||||||||||||||
-1,477 | -994 | -595 | -278 | 56 | 90 | 96 | 142 | 208 | 178 | - | - | - | - | - | - | - | - | -33 | -61 | -65 | -76 | -104 |
Other income | ||||||||||||||||||||||
182 | - | 0 | 60 | 0 | 144 | - | - | - | - | - | - | - | - | - | - | - | - | 432 | -1,278 | -96 | -6 | -81 |
Interest income | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 15 | 9 | 7 | - | 8 | 2 | - | - | - | - | - | - |
Interest income | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4 | - | - | - | - | - |
Interest expense | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10 | 18 | 29 | - | - | - | - | - |
Total other income (expense), net | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 15 | 9 | 7 | 1,104 | -2 | -16 | -25 | 399 | -1,339 | -161 | -82 | -185 |
Net loss | ||||||||||||||||||||||
-33,379 | -37,415 | -38,111 | -32,644 | -44,258 | -46,453 | -35,609 | -31,282 | -28,994 | -17,307 | -19,020 | -20,596 | -33,050 | -16,965 | -13,297 | -12,980 | -13,779 | -12,166 | -13,091 | -12,463 | -10,187 | -7,203 | -5,489 |
Other comprehensive (loss)/income: | ||||||||||||||||||||||
Unrealized gain/(loss) on available-for-sale securities | ||||||||||||||||||||||
- | - | 0 | 15 | 12 | -18 | -43 | -25 | 73 | 164 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Foreign currency translation adjustment | ||||||||||||||||||||||
-23 | -286 | 31 | -2 | 102 | -17 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total other comprehensive (loss)/income | ||||||||||||||||||||||
-23 | -286 | 31 | 13 | 114 | -35 | -48 | -25 | 73 | 164 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Comprehensive loss | ||||||||||||||||||||||
-33,402 | -37,701 | -38,080 | -32,631 | -44,144 | -46,488 | -35,657 | -31,307 | -28,921 | -17,143 | -19,198 | -20,596 | -33,050 | -16,965 | -13,297 | -12,980 | -13,779 | -12,166 | -13,091 | -12,463 | -10,187 | -7,203 | -5,489 |
Net loss | ||||||||||||||||||||||
-33,379 | -37,415 | -38,111 | -32,644 | -44,258 | -46,453 | - | -31,282 | -28,994 | - | - | - | - | - | - | -12,980 | -13,779 | -12,166 | -13,091 | -12,463 | -10,187 | -7,203 | -5,489 |
Accretion of redeemable convertible preferred stock | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 47 | 42 | 50 | 78 |
Net loss applicable to common stockholders | ||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13,091 | -12,510 | -10,229 | -7,253 | -5,567 |
Net loss per common share, basic and diluted | ||||||||||||||||||||||
-0.90 | -1.02 | -1.05 | -0.90 | -1.24 | -1.31 | -1.01 | -0.90 | -0.84 | -0.50 | -0.56 | -0.60 | -0.98 | -0.59 | -0.48 | -0.46 | -0.49 | -0.44 | 4.77 | -3.51 | -3.34 | -2.56 | -2.39 |
Weighted-average common shares outstanding, basic and diluted | ||||||||||||||||||||||
37,068 | 36,792 | 36,337 | 36,086 | 35,660 | 35,426 | 35,077 | 34,949 | 34,613 | 34,537 | 34,535 | 34,347 | 33,852 | 28,609 | 28,169 | 28,037 | 27,876 | 27,733 | 27,712 | 3,565 | 3,065 | 2,834 | 2,331 |